Chemical lethal dose testing determines the LD50 (median lethal dose) and LC50 (median lethal concentration) of chemical substances, providing the core toxicological data required for GHS classification, hazard labeling, safety data sheet authoring, and regulatory registration. Accredited third-party laboratories conduct acute oral, dermal, and inhalation toxicity studies in accordance with OECD, GB, EPA, and ISO test guidelines under GLP quality management systems. This article explains the sample types, testing items, methodologies, applicable standards, and practical applications involved in the lethal dose evaluation of chemical products.
Technical Overview
Lethal dose testing, also known as acute systemic toxicity testing, quantifies the intrinsic toxicity of a chemical substance by determining the dose or exposure concentration that causes mortality in test animals within a defined observation period. The principal endpoint is the LD50 (median lethal dose), expressed in milligrams of test substance per kilogram of body weight, or the LC50 (median lethal concentration) for inhalation exposure, expressed in milligrams per liter of air or parts per million over a specified duration, typically four hours.
Three exposure routes are conventionally evaluated: oral (gavage), dermal (occluded cutaneous application), and inhalation (nose-only or whole-body exposure chambers). The resulting data feed directly into hazard classification and labeling schemes under the UN Globally Harmonized System (GHS) and its regional implementations, including the EU CLP Regulation (EC) No 1272/2008, the US OSHA Hazard Communication Standard, and the Chinese national standard GB 30000.18 for acute toxicity classification.
Since the withdrawal of the classical OECD Test Guideline 401 in 2002, lethal dose determination has shifted toward humane, animal-sparing designs — the Fixed Dose Procedure (TG 420), the Acute Toxic Class Method (TG 423), and the Up-and-Down Procedure (TG 425) — which dramatically reduce animal use while delivering classification-grade results. Under GHS, acute oral toxicity is categorized on the basis of LD50 cutoff values:
- Category 1: LD50 ≤ 5 mg/kg body weight (fatal if swallowed)
- Category 2: 5 < LD50 ≤ 50 mg/kg body weight (fatal if swallowed)
- Category 3: 50 < LD50 ≤ 300 mg/kg body weight (toxic if swallowed)
- Category 4: 300 < LD50 ≤ 2000 mg/kg body weight (harmful if swallowed)
- Category 5: 2000 < LD50 ≤ 5000 mg/kg body weight (may be harmful if swallowed)
Testing Samples
Industrial and Specialty Chemicals
Raw materials, intermediates, solvents, monomers, catalysts, surfactants, dyes, and finished chemical preparations submitted for new chemical substance notification, REACH registration, or supply-chain hazard characterization. Both pure compounds and multi-component formulations can be evaluated, with vehicle selection and physicochemical pre-characterization (solubility, stability, vapor pressure, particle size) performed to design an appropriate dosing regimen.
Pharmaceutical Substances and Intermediates
Active pharmaceutical ingredients, drug candidates, excipients, and synthetic intermediates assessed during preclinical development. Single-dose toxicity studies in two mammalian species, as described in ICH guidance M3(R2), support first-in-human clinical trials and occupational exposure decisions for manufacturing personnel.
Pesticides and Agrochemical Products
Technical-grade active ingredients, co-formulants, and end-use formulations evaluated for registration under pesticide and biocide regulatory frameworks. Test programs typically follow EPA OPPTS 870 series guidelines or national pesticide toxicology standards such as the GB/T 15670 series.
Cosmetics, Household, and Consumer Products
Ingredients and finished products such as cleaning agents, detergents, air fresheners, paints, and coatings. Where animal testing is prohibited, for example for cosmetics marketed in the EU, classification is supported by validated in vitro methods, read-across, and quantitative structure–activity relationship (QSAR) modeling instead of animal-based lethal dose studies.
Food-Related and Feed Substances
Food additives, novel food ingredients, food contact materials, and feed additives evaluated under food safety toxicology programs, commonly using the acute oral toxicity test described in the national food safety standard GB 15193.3.
Medical Device Materials and Extracts
Polymer materials, elastomers, coatings, and device extracts assessed for acute systemic toxicity under ISO 10993-11 as part of the biocompatibility evaluation matrix for regulatory submission.
Testing Items
Lethal dose test programs are structured around the exposure route and the regulatory endpoint required. Core testing items include:
- Acute oral toxicity (LD50) — single-dose gavage administration, 14-day observation, GHS category assignment
- Acute dermal toxicity (LD50) — 24-hour occluded application to intact skin of rats or rabbits, 14-day observation
- Acute inhalation toxicity (LC50) — 4-hour nose-only or whole-body exposure to dusts, mists, vapors, or gases with aerosol characterization (MMAD, particle concentration)
- Limit tests at 2000 mg/kg (or 5000 mg/kg with justification) to demonstrate low acute toxicity without full dose-response evaluation
- Acute toxicity estimate (ATE) derivation for GHS labeling and mixture calculation
- Clinical sign observation, body-weight monitoring, and gross necropsy to identify target organs and toxicity thresholds
- Optional histopathological examination of major organs for dose-response characterization
Testing Methods
General In Vivo Study Design
Studies are performed on young adult rodents — rats for oral and inhalation routes, rats or rabbits for the dermal route — with female animals generally preferred. Following a single administration, animals are observed for at least 14 days with daily clinical inspections, scheduled body-weight recording, and gross necropsy of all animals. Humane endpoints and intensive monitoring are applied to minimize suffering, and all protocols require ethics committee approval under national animal welfare legislation.
Fixed Dose Procedure (OECD TG 420)
A sequential design using fixed dose levels of 5, 50, 300, and 2000 mg/kg. Dosing is stopped when evident toxicity rather than mortality is observed, allowing classification without a death-based endpoint. The method typically requires fewer than nine animals and yields an LD50 range suitable for GHS categorization.
Acute Toxic Class Method (OECD TG 423)
A stepwise procedure testing three animals of one sex per step at doses of 5, 50, 300, and 2000 mg/kg. Depending on the mortality pattern at each step, dosing either stops or moves to the next level. The outcome is a classification category or LD50 range rather than a precise point estimate, with substantially reduced animal use compared with the classical protocol.
Up-and-Down Procedure (OECD TG 425)
A sequential single-animal design in which each animal is dosed one at a time, with the dose for the next animal adjusted up or down according to the survival outcome. Results are analyzed by maximum-likelihood estimation, optionally adjusted with an in vitro cytotoxicity-derived starting dose. The method is particularly efficient for substances expected to be of low to moderate toxicity.
Dermal and Inhalation Studies
Acute dermal toxicity follows OECD TG 402, with a 24-hour occluded application to at least 10 percent of the body surface area and a limit test at 2000 mg/kg. Acute inhalation toxicity is conducted under OECD TG 403 (conventional LC50), TG 436 (Acute Toxic Class), or TG 433 (Fixed Concentration Procedure), using 4-hour exposures with verified atmosphere concentration, particle size distribution, and homogeneity.
National and Regional Standards
Chinese national standards GB/T 21603 (acute oral toxicity), GB/T 21604 (acute dermal toxicity), and GB/T 21605 (acute inhalation toxicity) specify domestic test methods for industrial chemicals, complemented by GB 15193.3 for food safety evaluation and GB 30000.18 for GHS-based classification and labeling. In the United States, the EPA OPPTS 870 series (870.1100 oral, 870.1200 dermal, 870.1300 inhalation) governs pesticide and industrial chemical testing. Medical device biocompatibility studies follow ISO 10993-11, and pharmaceutical programs reference ICH M3(R2).
Alternative Methods and the 3Rs
Consistent with the principles of Replacement, Reduction, and Refinement, regulatory frameworks increasingly accept computational and in vitro approaches, including QSAR prediction, read-across from structural analogues, and basal cytotoxicity assays such as neutral red uptake in BALB/c 3T3 cells for starting-dose estimation. These tools support category assignment and testing waivers while reducing or eliminating animal use.
Statistical Analysis and Reporting
Dose-response data are analyzed using probit or logit regression, the Spearman-Kärber method, the moving average method, or maximum-likelihood estimation depending on the study design. Reports present the LD50 or LC50 as a point estimate with 95 percent confidence intervals or as a bounding category, together with dose levels, sex-specific results, clinical observations, mortality timeline, body-weight curves, and necropsy findings. All studies are performed in compliance with OECD Principles of Good Laboratory Practice.
Applications
Lethal dose data serve as a gateway endpoint across nearly every chemical regulatory regime. Typical applications include:
- GHS, CLP, and GB 30000.18 hazard classification and labeling, including pictograms, signal words, and hazard statements
- Safety data sheet (SDS) authorization under REACH, OSHA HazCom, and GB/T 16483
- New chemical substance notification and registration dossiers in China, the EU, the United States, and other jurisdictions
- Pesticide and biocide product registration and active ingredient renewal
- Pharmaceutical preclinical packages supporting investigational new drug applications
- Transport of dangerous goods classification and packing group assignment under the UN Model Regulations
- Occupational health risk assessment, exposure limit derivation, and worker protection planning
- Research and development screening, formulation comparison, and product safety optimization
FAQ
What is the LD50 and how is it expressed?
The LD50 is the statistically derived single dose of a substance expected to cause death in 50 percent of test animals under defined conditions. It is expressed in mg/kg body weight for oral and dermal exposure, while inhalation results are expressed as an LC50 in mg/L or ppm for a four-hour exposure.
What is the difference between LD50 and LC50?
LD50 refers to a administered mass of substance per unit body weight (oral or dermal route), whereas LC50 refers to the concentration of the substance in air that causes 50 percent mortality during inhalation exposure. Both are acute toxicity endpoints but apply to different exposure routes and units.
Which test guideline should be selected?
The choice depends on the exposure route, the expected toxicity range, the regulatory framework, and animal welfare considerations. The Fixed Dose Procedure (TG 420) suits substances where evident toxicity can be observed; the Acute Toxic Class Method (TG 423) delivers category classification efficiently; and the Up-and-Down Procedure (TG 425) is efficient for moderately toxic substances expected to yield a precise point estimate. Accredited third-party laboratories can recommend the optimal design based on physicochemical properties and regulatory purpose.
Is the classical LD50 test with large animal groups still required?
No. The classical OECD TG 401 protocol was deleted in 2002 and has been replaced by the humane methods TG 420, TG 423, and TG 425, which require as few as four to twelve animals and use evident toxicity or sequential dosing rather than death as the primary decision criterion.
How long does lethal dose testing take?
A standard acute toxicity study includes acclimatization, a sighting or starting-dose phase, dosing, and a mandatory 14-day observation period, followed by necropsy and reporting. Typical turnaround is three to six weeks, depending on the protocol and whether dose escalation steps are needed.
Can animal testing be avoided?
In specific contexts, yes. Regulatory frameworks accept QSAR predictions, read-across from structurally related substances, existing weight-of-evidence data, and validated in vitro cytotoxicity results as grounds for waiving animal studies, particularly for cosmetics in regions with testing bans and for low-tonnage industrial chemicals with adequate analog data.
What sample quantity is required?
Required quantities depend on the route and dosing levels, generally ranging from tens of grams for oral and dermal limit tests to several hundred grams for full dose-response or inhalation studies, which also demand sufficient material to generate and characterize test atmospheres. Laboratories confirm exact amounts during the test plan review.
